Romano Brothers & Co’s Quest Diagnostics DGX Stock Holding History

Romano Brothers & Co’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27	Closed	-$4.16K	–	460
2022 Q4	$4.16K	Buy	+27	New	+$3.88K	﹤0.01%	866

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Romano Brothers & Co's DGX Position: Q1 2023 in Review

Romano Brothers & Co sold out of Quest Diagnostics (DGX) in Q1 2023, closing a stake of 27 shares — an estimated $4.16K sold.

Romano Brothers & Co first reported a position in DGX in Q4 2022 and held it in 1 quarter. The position peaked at $4.16K in Q4 2022. 834 funds tracked by Wall St. Rank hold DGX as of Q1 2023.

Romano Brothers & Co reported no remaining Quest Diagnostics position as of Q1 2023 after selling out during the quarter.
Romano Brothers & Co sold 27 Quest Diagnostics shares in Q1 2023, an estimated $4.16K.
Romano Brothers & Co first reported a position in Quest Diagnostics in Q4 2022 and held it in 1 quarter.
Romano Brothers & Co's Quest Diagnostics position peaked at $4.16K in Q4 2022.
834 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.